Cellular Therapy

Cellular Therapy (now operating as Rexgenero) is a clinical-stage regenerative medicine company focused on developing autologous cell therapies for serious diseases. The company's lead candidate, REX-001, is a pro-angiogenic cell therapy currently in Phase 3 clinical trials for the treatment of chronic limb-threatening ischemia (CLTI) in patients with peripheral arterial disease. Their technology leverages the patient's own bone marrow-derived mononuclear cells to stimulate blood vessel growth and improve blood flow to affected limbs. By focusing on autologous solutions, the company aims to provide effective treatments for vascular complications that currently have limited surgical or pharmacological options.